Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
Holding RVPH?
Track your performance easily
RVPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.60 - $6.80
Previous Close$1.21
Volume148.87K
Average Volume (3M)481.61K
Market Cap
$40.04M
Enterprise Value$34.07M
Total Cash (Recent Filing)$6.18M
Total Debt (Recent Filing)$207.50K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Nov 11, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding33,090,000
10 Day Avg. Volume213,462
30 Day Avg. Volume481,612
Standard Deviation0.49
R-Squared0.00005
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-6.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$14.50Price Target Upside1139.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Reviva Pharmaceuticals Holdings News
PremiumCompany Announcements
Reviva Pharmaceuticals Launches Multi-Million Share Offering
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyNew brilaroxazine patent granted in Europe.
Orphan Drug DesignationBrilaroxazine has received Orphan Drug Designation from the FDA for the treatment of PAH.
Regulatory MilestonesFDA alignment has been secured for the study design of the upcoming P3 'RECOVER-2' study.
Bears Say
Financial PerformanceReviva reported a net loss of ($7.9M) and ended the period with $6.2M in cash on the balance sheet.
Funding And Capital NeedsThe company has postponed the initiation of its second Phase 3 study, likely due to funding constraints.
Risks And ChallengesRisks include, but are not limited to: inability to complete pivotal development of brilaroxazine in schizophrenia in a timely manner, negative top-line data from the confirmatory pivotal trial of brilaroxazine in schizophrenia, failure to obtain approval of brilaroxazine in schizophrenia, failure to establish a commercial partnership to effectively market brilaroxazine globally, slower-than-anticipated adoption of brilaroxazine due to competitive landscape changes, availability of cheaper generic agents or other factors, and near-term dilution risk.
---
Ownership Overview
6.35%
Insiders
3.75% Mutual Funds
8.10% Other Institutional Investors
78.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.60 and its highest was $6.80 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Currently, no data Available
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Nov 11, 2024 which is in 32 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Aug 14, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.042.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -$0.25.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 33,093,555 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Among the largest hedge funds holding Reviva Pharmaceuticals Holdings’s share is Woodline Partners LP. It holds Reviva Pharmaceuticals Holdings’s shares valued at 2M.
---
Reviva Pharmaceuticals Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.50 (1139.32% Upside)
$14.50 (1139.32% Upside)
Blogger Sentiment
Bullish
RVPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 537.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.00%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
---
RVPH Stock 12 Month Forecast
Average Price Target
$14.50
▲(1139.32% Upside)
Technical Analysis
Best Analysts Covering RVPH
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-46.93%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -46.93% per trade.
---